As millions of patients with HIV/AIDS are put on treatment with the highly active antiretroviral
therapy (HAART), drug interactions have become a major concern for healthcare providers …

Like any other drug, antimicrobial drugs are prone to pharmacokinetic drug interactions.
These drug interactions are a major concern in clinical practice as they may have an effect …

Compared to rifampicin (600 mg/day), standard doses of rifabutin (300 mg/day) have a lower
risk of drug–drug interactions due to induction of cytochrome P450 3A4 (CYP3A4) or P …

Acinetobacter baumannii has among the highest rates of antibiotic resistance encountered
in hospitals. New therapies are critically needed. We found that rifabutin has previously …

The drug-drug interaction between rifabutin (RFB) and darunavir/ritonavir (DRV/r) was
examined in a randomized, three-way crossover study of HIV-negative healthy volunteers …

Raltegravir is an HIV‐1 integrase strand transfer inhibitor with potent activity against HIV‐1.
A prior investigation of raltegravir coadministered with rifampin demonstrated a decrease in …

Rifabutin (RFB) is administered for treatment of tuberculosis and Mycobacterium avium
complex infection, including use for patients coinfected with human immunodeficiency virus …

Background Methadone disposition and pharmacodynamics are highly susceptible to
interactions with antiretroviral drugs. Methadone clearance and drug interactions have been …

Rifampicin is a strong inducer of cytochrome P450 (CYP3A4) and P-glycoprotein (P-
gp/ABCB1), leading to profound drug–drug interactions. In contrast, the chemically related …

Objectives Extensive but fragmented data from existing studies were used to describe the
drug–drug interaction between rifabutin and HIV PIs and predict doses achieving …